Your browser doesn't support javascript.
loading
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
Scordo, Michael; Flynn, Jessica R; Gonen, Mithat; Devlin, Sean M; Parascondola, Allison; Tomas, Ana Alarcon; Shouval, Roni; Brower, Jamie; Porter, David L; Schuster, Stephen J; Bachanova, Veronika; Maakaron, Joseph; Maziarz, Richard T; Chen, Andy I; Nastoupil, Loretta J; McGuirk, Joseph P; Oluwole, Olalekan O; Ip, Andrew; Leslie, Lori A; Bishop, Michael R; Riedell, Peter A; Perales, Miguel-Angel.
Afiliação
  • Scordo M; Adult Bone Marrow Transplant Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Flynn JR; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Gonen M; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Devlin SM; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Parascondola A; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Tomas AA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Shouval R; Department of Hematology, Hospital Gregorio Marañón, Madrid, Spain.
  • Brower J; Adult Bone Marrow Transplant Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Porter DL; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Schuster SJ; Cell Therapy and Transplant and Lymphoma Programs, Division of Hematology-Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Bachanova V; Cell Therapy and Transplant and Lymphoma Programs, Division of Hematology-Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Maakaron J; Cell Therapy and Transplant and Lymphoma Programs, Division of Hematology-Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Maziarz RT; Division of Hematology, Oncology and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
  • Chen AI; Division of Hematology, Oncology and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
  • Nastoupil LJ; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
  • McGuirk JP; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
  • Oluwole OO; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ip A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.
  • Leslie LA; Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN.
  • Bishop MR; Division of Lymphoma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.
  • Riedell PA; Department of Oncology, Hackensack Meridian School of Medicine, Nutley, NJ.
  • Perales MA; Division of Lymphoma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.
Blood Adv ; 7(18): 5579-5585, 2023 09 26.
Article em En | MEDLINE | ID: mdl-37522731
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Imunoterapia Adotiva Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Imunoterapia Adotiva Idioma: En Ano de publicação: 2023 Tipo de documento: Article